ATE400814T1 - Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum - Google Patents

Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Info

Publication number
ATE400814T1
ATE400814T1 AT00982293T AT00982293T ATE400814T1 AT E400814 T1 ATE400814 T1 AT E400814T1 AT 00982293 T AT00982293 T AT 00982293T AT 00982293 T AT00982293 T AT 00982293T AT E400814 T1 ATE400814 T1 AT E400814T1
Authority
AT
Austria
Prior art keywords
pin1
cell growth
abnormal cell
metastasization
aggressivity
Prior art date
Application number
AT00982293T
Other languages
English (en)
Inventor
Kun Lu
Gerburg Wulf
Xiao Zhou
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE400814T1 publication Critical patent/ATE400814T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AT00982293T 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum ATE400814T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16780099P 1999-11-29 1999-11-29
US25367600P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
ATE400814T1 true ATE400814T1 (de) 2008-07-15

Family

ID=26863487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982293T ATE400814T1 (de) 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Country Status (7)

Country Link
EP (1) EP1234185B1 (de)
JP (1) JP2003515172A (de)
AT (1) ATE400814T1 (de)
CA (1) CA2392917C (de)
DE (1) DE60039453D1 (de)
HK (1) HK1051066A1 (de)
WO (1) WO2001038878A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073096A1 (en) * 2001-02-09 2003-04-17 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
EP1368630A4 (de) * 2001-02-09 2004-06-16 Pintex Pharmaceuticals Inc Pin1 als marker für abnormales zellwachstum
AU2002322199B2 (en) * 2001-09-12 2009-06-04 The Walter And Eliza Hall Institute Of Medical Research A method of diagnosis and treatment and agents useful for same
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
EP1572236A4 (de) 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc Pin1-spiegel in normalem gewebe sowie in krebsgewebe
WO2022032179A1 (en) * 2020-08-07 2022-02-10 The Regents Of The University Of California Pin1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
DE60039453D1 (de) 2008-08-21
HK1051066A1 (zh) 2003-07-18
WO2001038878A2 (en) 2001-05-31
WO2001038878A3 (en) 2002-01-17
CA2392917A1 (en) 2001-05-31
CA2392917C (en) 2007-05-01
EP1234185B1 (de) 2008-07-09
JP2003515172A (ja) 2003-04-22
EP1234185A2 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
WO2002065091A3 (en) Pin1 as marker for abnormal cell growth
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
ATE463092T1 (de) Busmodem für gebäude- und industrielle elektrische systeme
WO2003048300A3 (en) Methods of identifying cellular target molecules
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003302732A1 (en) Method for identifying risk of breast cancer and treatments thereof
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
ATE400814T1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
DE69837153D1 (de) Verhinderung des zellwachstums in einem gewässer
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2004081521A3 (en) Methods for direct detection of individual methotrexate metabolites
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
ATE393917T1 (de) Identifikation von therapeutische verbindungen.
GB9916810D0 (en) Killing cells
EP1601682A4 (de) Verbindungen und verfahren zur diagnose und behandlung von prostatakrebs
WO2004046329A3 (en) Levels of pin1 in normal and cancerous tissue
WO2007143066A3 (en) Method for predicting susceptibility to radiation pneumonitis
WO2001046468A3 (en) Screening method for ros-induced apoptosis in a cell

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties